Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
Subscribe To Our Newsletter & Stay Updated